Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.57 |
| ▸ | RBP4 | P02753 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HMOX1 | P09601 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086151 | 0.89 | RBP4 (0.49) | METRBP4MAPK1HMOX1DPP4 | |
| SCHEMBL4084428 | 0.84 | MET (0.46) | METRBP4MAPK1DPP4DPP8 | |
| SCHEMBL4093739 | 0.80 | HMOX1 (0.50) | METRBP4MAPK1HMOX1FLT3 | |
| SCHEMBL4094306 | 0.79 | CTSS (0.60) | — | |
| SCHEMBL4084425 | 0.79 | CTSS (0.49) | — | |
| SCHEMBL4090657 | 0.78 | CTSS (0.58) | — | |
| SCHEMBL5257069 | 0.78 | MAPK1 (0.63) | METRBP4MAPK1HMOX1FLT3 | |
| SCHEMBL4086108 | 0.76 | CTSS (0.59) | — | |
| SCHEMBL4089732 | 0.76 | CTSS (0.54) | — | |
| SCHEMBL4080410 | 0.75 | CTSS (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | MET 4449/4885RBP4 3080/4885MAPK1 2735/4885 |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | MET 3516/4885RBP4 3546/4885MAPK1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.